Recruiting studies: Epidermal Growth Factor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre
Phase 3 · 250 location(s) · AstraZeneca · NCT06989112 Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molec
NA · 1 location(s) · Guangzhou Medical University · NCT06304441 A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Phase 2 · 5 location(s) · National Cancer Center, Korea · NCT06156527 Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase 1 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT06934889 A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Phase 1 · 1 location(s) · Kind Pharmaceuticals LLC · NCT05187832 Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Assoc
Phase 2 · 12 location(s) · Hoth Therapeutics, Inc. · NCT05639933 A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871 Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Phase 2 · 10 location(s) · Mark Vincent · NCT04335292 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 3 · 249 location(s) · Astellas Pharma Global Development, Inc. · NCT06901531 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor E
Phase 1 · 1 location(s) · Tongji University · NCT07361237 Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Br
Phase 2 · 6 location(s) · AstraZeneca · NCT07427394 Target-specific immunoPET Imaging of Digestive System Carcinoma
NA · 1 location(s) · RenJi Hospital · NCT06715839 A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent
Phase 3 · 25 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07003074 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub
Phase 3 · 303 location(s) · AstraZeneca · NCT06417814 Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic B
Phase 2 · 8 location(s) · SCRI Development Innovations, LLC · NCT05748834 TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428 Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05983107 A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-m
Phase N/A · 34 location(s) · Alpha Biopharma (Jiangsu) Co., Ltd. · NCT07143045 First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
Phase 1/Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT05271916 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997 Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Ne
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06964906 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer Aft
Phase 2/Phase 3 · 186 location(s) · Bristol-Myers Squibb · NCT07100080 A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed,
Phase 3 · 2 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT07071337 HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Phase 2 · 7 location(s) · Abscint NV/SA · NCT06369831 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI
Phase 3 · 211 location(s) · Relay Therapeutics, Inc. · NCT06982521 PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Phase 1 · 1 location(s) · Henry Ford Health System · NCT04886726 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655 A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced o
Phase 3 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07183189

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →